Pubblicazioni

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

2022 - THE LANCET. HAEMATOLOGY

Dimopoulos, Meletios A; Richardson, Paul G; Bahlis, Nizar J; Grosicki, Sebastian; Cavo, Michele; BeksaÃ§, Meral; LegieÄ, Wojciech; Liberati, Anna M; Goldschmidt, Hartmut; Belch, Andrew; Magen, Hila; Larocca, Alessandra; Laubach, Jacob P; Petrucci, Maria T; Reece, Donna; White, Darrell; Mateos, MarÃa-Victoria; Å piÄka, Ivan; Lazaroiu, Mihaela; Berdeja, JesÃºs; Kaufman, Jonathan L; Jou, Ying-Ming; Ganetsky, Alex; Popa McKiver, Mihaela; Lonial, Sagar; Weisel, Katja; Martelli, Maurizio

IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study

2021 - CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

Lawless, S; Sbianchi, G; Morris, C; Iacobelli, S; Bosman, P; Blaise, D; Remenyi, P; Byrne, Jl; Mayer, J; Apperley, J; Lund, J; Kobbe, G; Schaap, N; Isaksson, C; Lenhoff, S; Basak, G; Touzeau, C; Wilson, Kmo; Muniz, Sg; Scheid, C; Browne, P; Anagnostopoulos, A; Rambaldi, A; Jantunen, E; Kroger, N; Schonland, S; Yakoub-Agha, I; Garderet, L

Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP

2020 - EUROPEAN JOURNAL OF HAEMATOLOGY

Hayden, Patrick J; Iacobelli, Simona; PÃ©rez-SimÃ³n, JosÃ© Antonio; van Biezen, Anja; Minnema, Monique; Niittyvuopio, Riitta; SchÃ¶nland, Stefan; Meijer, Ellen; Blaise, Didier; Milpied, Noel; MÃ¡rquez-Malaver, Francisco J; Veelken, Joan Hendrik; Maertens, Johan; Michallet, Mauricette; Cammenga, JÃ¶rg; N'Guyen, Stephanie; Niederwieser, Dietger; Hunault-Berger, Mathilde; Bourhis, Jean Henri; Passweg, Jakob; Bermudez, Arancha; Chalandon, Yves; Yakoub-Agha, Ibrahim; Garderet, Laurent; KrÃ¶ger, Nicolaus

Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma

2018 - NEW ENGLAND JOURNAL OF MEDICINE

Mateos, M. -V.; Dimopoulos, M. A.; Cavo, M.; Suzuki, K.; Jakubowiak, A.; Knop, S.; Doyen, C.; Lucio, P.; Nagy, Z.; Kaplan, P.; Pour, L.; Cook, M.; Grosicki, S.; Crepaldi, A.; Liberati, A. M.; Campbell, P.; Shelekhova, T.; Yoon, S. -S.; Iosava, G.; Fujisaki, T.; Garg, M.; Chiu, C.; Wang, J.; Carson, R.; Crist, W.; Deraedt, W.; Nguyen, H.; Qi, M.; San-Miguel, J.; Foa, R.

Diffusion-weighted whole-body MRI for evaluation of early response in multiple myeloma

2017 - CLINICAL RADIOLOGY

Lacognata, C.; Crimi, F.; Guolo, A.; Varin, C.; De March, E.; Vio, S.; Ponzoni, A.; Barila, G.; Lico, A.; Branca, A.; De Biasi, E.; Gherlinzoni, F.; Scapin, V.; Bissoli, E.; Berno, T.; Zambello, R.